Key Takeaways
- • CVC Capital Partners and Groupe Bruxelles Lambert (GBL) launched a €10.7 billion ($12.4 billion) cash bid to take Italian pharmaceutical company Recordati private, valuing shares at €51.29 per share—a 13% premium to the market price.
- • The tender offer aims to fully delist Recordati from Euronext Milan, with CVC holding a controlling 46.8% stake in the company since 2018 through a dedicated investment vehicle.
- • The privatization strategy is designed to unlock value across Recordati's fragmented business lines—primary care, consumer health, rare diseases, and pharmaceutical chemicals—by enabling pursuit of strategic acquisitions and expansion opportunities without public market constraints.
- • The transaction reflects broader consolidation momentum in Italy's pharmaceutical sector, following recent deals including Angelini's $4.1 billion acquisition of Catalyst Pharmaceuticals and Chiesi's $2 billion purchase of KalVista Pharmaceuticals.
- • The non-binding expression of interest was initially submitted at the end of March, conditional on identifying financial partners; the formal bid now represents CVC and GBL's commitment to proceed with the acquisition.
Summary
CVC Capital Partners and Groupe Bruxelles Lambert launched a formal €10.7 billion cash offer on May 22, 2026, to acquire full control of Recordati and delist the Italian pharmaceutical company from Euronext Milan. The bid values each share at €51.29, representing approximately a 13% premium to prevailing market prices. The transaction, structured through a newly formed Italian joint stock company, requires approval from Recordati's board and represents one of the largest recent acquisitions in Italy's fragmented pharmaceutical sector.
CVC has maintained a controlling stake in Recordati since 2018, when it first invested in the company through a dedicated holding vehicle currently representing 46.8% ownership. The consortium initially submitted a non-binding expression of interest at the end of March 2026, contingent on securing additional financial partners to support the bid. The current formal offer resolves this condition and signals the sponsors' commitment to completing the transaction.
The strategic rationale centers on operational flexibility unavailable to a publicly traded company. By taking Recordati private, CVC and GBL aim to pursue acquisitions and strategic partnerships across the company's diverse business divisions—primary care, consumer health, rare diseases, and pharmaceutical chemicals manufacturing—without the disclosure requirements and capital allocation constraints of public markets. This approach reflects a broader consolidation trend among Italian pharmaceutical companies seeking scale and specialization; Angelini recently announced a $4.1 billion acquisition of U.S.-listed Catalyst Pharmaceuticals, while Chiesi acquired KalVista Pharmaceuticals for approximately $2 billion.
Recordati, founded over a century ago as a family pharmacy in central Italy, has evolved into a diversified pharmaceutical platform with significant presence across multiple therapeutic areas and business models. The delisting would provide management and sponsors with the operational autonomy to pursue value-creation initiatives across these separate entities, a key driver of the private equity consortium's investment thesis. The transaction now awaits board consideration and customary regulatory approvals for completion.
CVC has maintained a controlling stake in Recordati since 2018, when it first invested in the company through a dedicated holding vehicle currently representing 46.8% ownership. The consortium initially submitted a non-binding expression of interest at the end of March 2026, contingent on securing additional financial partners to support the bid. The current formal offer resolves this condition and signals the sponsors' commitment to completing the transaction.
The strategic rationale centers on operational flexibility unavailable to a publicly traded company. By taking Recordati private, CVC and GBL aim to pursue acquisitions and strategic partnerships across the company's diverse business divisions—primary care, consumer health, rare diseases, and pharmaceutical chemicals manufacturing—without the disclosure requirements and capital allocation constraints of public markets. This approach reflects a broader consolidation trend among Italian pharmaceutical companies seeking scale and specialization; Angelini recently announced a $4.1 billion acquisition of U.S.-listed Catalyst Pharmaceuticals, while Chiesi acquired KalVista Pharmaceuticals for approximately $2 billion.
Recordati, founded over a century ago as a family pharmacy in central Italy, has evolved into a diversified pharmaceutical platform with significant presence across multiple therapeutic areas and business models. The delisting would provide management and sponsors with the operational autonomy to pursue value-creation initiatives across these separate entities, a key driver of the private equity consortium's investment thesis. The transaction now awaits board consideration and customary regulatory approvals for completion.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.